세계 수막구균 백신 시장 규모는 2024년 39억 달러에 달했습니다. IMARC Group은 시장이 2033년까지 76억 달러에 달하고, 2025-2033년 7.3%의 연평균 성장률(CAGR)을 보일 것으로 예측했습니다. 수막구균 감염 부담 증가, 정부 예방접종 프로그램, 지속적인 기술 발전, 세계 보건 안보에 대한 우려는 주로 시장 성장의 원동력이 되고 있습니다.
수막염 세균성 질환의 유병률 상승
수막구균성 질환의 유병률 증가는 수막구균 백신에 대한 수요를 촉진하는 중요한 요인입니다. 예를 들어, 세계보건기구(WHO)에 따르면 2022년 11월부터 2023년 1월까지 니제르 남동부 진데르 지역에서는 2021년 11월부터 2022년 1월까지 보고된 231건과 비교하여 18명의 사망자를 포함한 약 559건의 수막염이 기록되었습니다. 수막구균 감염은 수막구균에 의해 발생하며, 빠른 발병, 중증화, 집단 발생 가능성으로 인해 여전히 전 세계 보건에 심각한 우려를 불러일으키고 있습니다. 높은 질병 부담은 효과적인 백신에 대한 수요를 촉진하고 있습니다. 이러한 요인들은 향후 수막구균 백신 시장의 성장 동력이 될 것으로 예측됩니다.
계몽 프로그램 증가
공중보건 캠페인, 의료진 교육, 지역사회 홍보를 통해 수막구균 감염과 백신 접종의 중요성에 대한 인식이 높아지고 있습니다. 예를 들어, 2021년 8월, GSK는 'Ask2BSure'라는 공중보건 캠페인을 통해 부모가 자녀의 주치의에게 수막구균 B형간염 예방접종 여부를 확인하도록 촉구했습니다. 수막구균성 질환은 흔히 수막염으로 알려져 있으며, 드물지만 치명적일 수 있는 질환입니다. 백신에 대한 이해가 깊어지면 백신의 수용과 섭취가 촉진됩니다. 이러한 요인들은 수막구균 백신 시장 예측에 더욱 긍정적인 영향을 미칠 것입니다.
정부 예방접종 프로그램
많은 국가에서 영유아, 청소년, 고위험군을 대상으로 수막구균 백신을 포함한 정기 예방접종 스케줄을 수립하고 있습니다. 예를 들어, 서호주 보건부의 2022년 11월 업데이트에 따르면, 학교 기반 예방접종 프로그램(SBIP)은 2023년부터 디프테리아 파상풍 백일해(dTpa), HPV(인간유두종바이러스), 수막구균 ACWY 백신을 학생들에게 제공할 예정입니다. 마찬가지로 2023년 8월, 퀸즐랜드 주정부는 향후 3년간 9,000만 달러를 투자하여 영유아 및 성인에게 수막염 B 백신 무료 접종을 실시할 계획이며, 이는 수막염 백신 시스템 시장의 매출을 촉진할 것입니다.
The global meningococcal vaccines market size reached USD 3.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.6 Billion by 2033, exhibiting a growth rate (CAGR) of 7.3% during 2025-2033. The increasing burden of meningococcal disease, government immunization programs, ongoing technological advancements, and global health security concerns are driving the primarily driving the market growth.
Rising Prevalence of Meningococcal Disease
The rising prevalence of meningococcal disease is a significant factor driving the demand for meningococcal vaccines. For instance, according to the World Health Organization (WHO), from November 2022 to January 2023, around 559 cases of meningitis, including 18 deaths, were recorded from Zinder Region, southeast of Niger, compared to 231 cases reported from November 2021 to January 2022. Meningococcal disease, caused by Neisseria meningitidis bacteria, remains a significant global health concern due to its potential for rapid onset, severity, and outbreaks. The high disease burden drives the demand for effective vaccines. These factors are expected to propel the meningococcal vaccines market in the coming years.
Increasing Awareness Programs
Public health campaigns, healthcare provider education, and community outreach efforts have increased awareness about meningococcal disease and the importance of vaccination. For instance, in August 2021, GSK introduced "Ask2BSure," a public health campaign to encourage parents to check with their child's doctor to see if they have meningitis B immunization. Meningococcal disease, often known as meningitis, is a rare but potentially fatal condition. Enhanced understanding promotes vaccine acceptance and uptake. These factors further positively influence the meningococcal vaccines market forecast.
Government Immunization Programs
Many countries have established routine immunization schedules that include meningococcal vaccines, targeting infants, adolescents, and high-risk groups. For example, according to a November 2022 update from the Government of Western Australia Department of Health, the School-Based Immunization Program (SBIP) would provide Diphtheria-tetanus-pertussis (dTpa), HPV (human papillomavirus), and Meningococcal ACWY vaccines to students beginning 2023. Similarly, in August 2023, the Queensland Government planned to invest US$ 90 million over the next three years to offer free meningococcal B vaccine vaccinations for young children and adults, thereby boosting the meningococcal vaccine systems market revenue.
According to the meningococcal vaccines market outlook, conjugate vaccines are composed of polysaccharide antigens from the bacterial capsule of Neisseria meningitidis, chemically linked (conjugated) to a carrier protein. While polysaccharide vaccines contain purified polysaccharide antigens derived from the bacterial capsule of Neisseria meningitidis. Moreover, subcapsular vaccines target specific surface proteins or antigens located within the bacterial capsule or outer membrane of Neisseria meningitidis.
According to the meningococcal vaccines market overview, monovalent vaccines are often in demand during outbreaks or localized epidemics caused by specific meningococcal serogroup. Public health authorities may deploy monovalent vaccines to quickly contain outbreaks and prevent further spread of the disease. While combination vaccines that protect against multiple meningococcal serogroups (e.g., MenACWY) are favored for routine immunization schedules. They streamline vaccination programs by reducing the number of injections and clinic visits required to achieve comprehensive protection.
MenACWY vaccines protect against meningococcal serogroups A, C, W, and Y. While MenB vaccines target meningococcal serogroup B. MenB vaccines are typically recombinant protein-based or outer membrane vesicle (OMV) vaccines. They contain antigens specific to serogroup B, which are distinct in structure from serogroups A, C, W, and Y. Moreover, MenAC vaccines target meningococcal serogroups A and C. Apart from this, MenA vaccines specifically target meningococcal serogroup A. These are typically monovalent vaccines containing polysaccharide antigens from serogroup A Neisseria meningitidis. Furthermore, MenACWY-DT vaccines combine antigens from meningococcal serogroups A, C, W, and Y.
Hospitals often administer meningococcal vaccines to patients admitted for various reasons, including those at higher risk of contracting meningococcal disease due to immunocompromised status or underlying conditions. Hospital pharmacies may provide vaccinations to individuals requiring preventive care or as part of travel medicine services. While retail pharmacies cater to the general public, offering convenient access to meningococcal vaccines for individuals seeking preventive healthcare. Apart from this, institutional sales involve large-scale procurement of meningococcal vaccines for public health programs, such as national immunization schedules targeting specific age groups or high-risk populations.
Meningococcal vaccines, such as MenACWY, are included in routine childhood immunization schedules in many countries. Vaccination typically begins in infancy and continues through childhood, with doses administered according to national guidelines. While young adults who missed meningococcal vaccination during adolescence may receive catch-up doses, especially before entering college or university. College and university dormitories often require proof of meningococcal vaccination, boosting demand among this age group.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
According to the meningococcal vaccines market statistics, the rising prevalence of meningococcal disease in North America is a primary driver. Meningococcal infections can lead to severe outcomes, including meningitis and sepsis, which have spurred vaccination efforts. While stringent healthcare policies and regulations in Europe support the adoption and inclusion of meningococcal vaccines in national immunization schedules. This regulatory environment provides stability and encourages vaccine development and distribution. Apart from this, the Asia Pacific region has seen an increase in the incidence of meningococcal disease, prompting higher demand for vaccines.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: